trending Market Intelligence /marketintelligence/en/news-insights/trending/g1qiil9te9h2b0tdwtz3mg2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

MeiraGTx genetic eye therapy receives US FDA orphan drug designation


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

MeiraGTx genetic eye therapy receives US FDA orphan drug designation

MeiraGTx Holdings PLC said the U.S. Food and Drug Administration has granted orphan drug designation to its gene therapy AAV-CNGA3.

The gene therapy is a potential treatment of achromatopsia, a hereditary visual disorder that causes absence of color vision, decreased vision, light sensitivity and involuntarily movement of the eyes. The therapy will receive seven-year market exclusivity if approved with an orphan drug designation, the company said Aug. 13. Orphan designation facilitates and expedites the development of drugs for rare diseases.

MeiraGTx has previously received a positive recommendation for orphan drug status from the European Medicines Agency for the therapy.

New York-based MeiraGTx is a clinical-stage gene therapy company with four ongoing clinical programs and a broad pipeline of preclinical and research programs for the treatment of a range of inherited and acquired disorders.